ACE and mastodynia: Furthermore, spironolactone’s hormonal side effects—gynecomastia or mastodynia—were reported in approximately 10% of men, and the risk of hyperkalemia, although low within the trial, became a major concern in clinical practice, especially when combined with ACE inhibitors.